These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 25576921)

  • 61. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 62. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.
    Shen Y; Rehman FL; Feng Y; Boshuizen J; Bajrami I; Elliott R; Wang B; Lord CJ; Post LE; Ashworth A
    Clin Cancer Res; 2013 Sep; 19(18):5003-15. PubMed ID: 23881923
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy.
    Liang J; Piao Y; Henry V; Tiao N; de Groot JF
    Oncotarget; 2015 Oct; 6(31):31479-92. PubMed ID: 26362401
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
    Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC
    Oncotarget; 2015 Oct; 6(31):30773-86. PubMed ID: 26356822
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies.
    Gaymes TJ; Mohamedali AM; Patterson M; Matto N; Smith A; Kulasekararaj A; Chelliah R; Curtin N; Farzaneh F; Shall S; Mufti GJ
    Haematologica; 2013 Sep; 98(9):1397-406. PubMed ID: 23349304
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition.
    Xia Q; Cai Y; Peng R; Wu G; Shi Y; Jiang W
    Int J Oncol; 2014 Mar; 44(3):735-44. PubMed ID: 24378347
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity.
    Smeby J; Kryeziu K; Berg KCG; Eilertsen IA; Eide PW; Johannessen B; Guren MG; Nesbakken A; Bruun J; Lothe RA; Sveen A
    EBioMedicine; 2020 Sep; 59():102923. PubMed ID: 32799124
    [TBL] [Abstract][Full Text] [Related]  

  • 68.
    Cancer Discov; 2017 Apr; 7(4):OF4. PubMed ID: 28228392
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Suppression of tumor growth via IGFBP3 depletion as a potential treatment in glioma.
    Chen CH; Chen PY; Lin YY; Feng LY; Chen SH; Chen CY; Huang YC; Huang CY; Jung SM; Chen LY; Wei KC
    J Neurosurg; 2020 Jan; 132(1):168-179. PubMed ID: 30641835
    [TBL] [Abstract][Full Text] [Related]  

  • 70. PDGF Engages an E2F-USP1 Signaling Pathway to Support ID2-Mediated Survival of Proneural Glioma Cells.
    Rahme GJ; Zhang Z; Young AL; Cheng C; Bivona EJ; Fiering SN; Hitoshi Y; Israel MA
    Cancer Res; 2016 May; 76(10):2964-76. PubMed ID: 26951930
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer.
    Mansour WY; Tennstedt P; Volquardsen J; Oing C; Kluth M; Hube-Magg C; Borgmann K; Simon R; Petersen C; Dikomey E; Rothkamm K
    Sci Rep; 2018 Mar; 8(1):3947. PubMed ID: 29500400
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?
    Lester A; Rapkins R; Nixdorf S; Khasraw M; McDonald K
    Clin Transl Oncol; 2017 Mar; 19(3):273-278. PubMed ID: 27655368
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparative status of activated ERK1/2 and PARP cleavage in human gliomas.
    Bhaskara VK; Panigrahi M; Challa S; Babu PP
    Neuropathology; 2005 Mar; 25(1):48-53. PubMed ID: 15822818
    [TBL] [Abstract][Full Text] [Related]  

  • 74. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.
    Russo AL; Kwon HC; Burgan WE; Carter D; Beam K; Weizheng X; Zhang J; Slusher BS; Chakravarti A; Tofilon PJ; Camphausen K
    Clin Cancer Res; 2009 Jan; 15(2):607-12. PubMed ID: 19147766
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Sustained inhibition of PARP-1 activity delays glioblastoma recurrence by enhancing radiation-induced senescence.
    Ghorai A; Mahaddalkar T; Thorat R; Dutt S
    Cancer Lett; 2020 Oct; 490():44-53. PubMed ID: 32645394
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor.
    Xiong Y; Guo Y; Liu Y; Wang H; Gong W; Liu Y; Wang X; Gao Y; Yu F; Su D; Wang F; Zhu Y; Zhao Y; Wu Y; Qin Z; Sun X; Ren B; Jiang B; Jin W; Shen Z; Tang Z; Song X; Wang L; Liu X; Zhou C; Jiang B
    Neoplasia; 2020 Sep; 22(9):431-440. PubMed ID: 32652442
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1.
    Jain MR; Mohapatra J; Bandhyopadhyay D; Chatterjee A; Ghoshdastidar K; Patel D; Patel A; Bhayani H; Srivastava BK; Shedage SA; Kadam P; Sundar R; Patel H; Giri P; Patel P; Gupta L; Srinivas NR; Patel PR; Desai RC
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):635-647. PubMed ID: 30046848
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene.
    Wang L; Cai W; Zhang W; Chen X; Dong W; Tang D; Zhang Y; Ji C; Zhang M
    Oncotarget; 2015 Sep; 6(29):27490-504. PubMed ID: 26314963
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Aberrant mesenchymal differentiation of glioma stem-like cells: implications for therapeutic targeting.
    Balasubramaniyan V; Vaillant B; Wang S; Gumin J; Butalid ME; Sai K; Mukheef F; Kim SH; Boddeke HW; Lang F; Aldape K; Sulman EP; Bhat KP; Colman H
    Oncotarget; 2015 Oct; 6(31):31007-17. PubMed ID: 26307681
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome.
    Cesarini V; Martini M; Vitiani LR; Gravina GL; Di Agostino S; Graziani G; D'Alessandris QG; Pallini R; Larocca LM; Rossi P; Jannini EA; Dolci S
    Oncotarget; 2017 Feb; 8(8):13223-13239. PubMed ID: 28099939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.